Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3 mg) produce significant body weight reduction (up to 20% with semaglutide) and improve cardiovascular risk factors, with semaglutide showing superiority in weight loss compared to previous drugs.
If lifestyle changes alone aren't enough, GLP-1 medications like semaglutide (2.4 mg weekly) are highly effective, producing up to 20% body weight loss in many patients. This weight loss is comparable to bariatric surgery and significantly improves blood pressure and cardiovascular risk. Discuss these options with your doctor if you have obesity and comorbidities.
Treatment with semaglutide produced a 5% reduction of body weight in >90% of subjects and a 20% reduction in about 35%, these results being comparable to those achieved with BMS.
Why this rating
Cites multiple large clinical trials (STEP, SCALE, SELECT) and meta-analyses.
Source
Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)
Massimo Volpe et al. · Frontiers in Cardiovascular Medicine · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →